Affiliation:
1. National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
2. Institute of Blood and Marrow Transplantation Collaborative Innovation Center of Hematology Soochow University Suzhou China
3. Institute of Biomedical Engineering and Technology Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development School of Chemistry and Molecular Engineering East China Normal University Shanghai China
Abstract
AbstractDual‐targeted chimeric antigen receptor T (CAR‐T) cell is an important strategy to improve the efficacy of CD19 CAR‐T cell against refractory or relapsed B cell non‐Hodgkin lymphoma (R/R B‐NHL). However, durable responses are not achieved in most patients, in part owing CAR‐T cell exhaustion caused by PD‐1/PD‐L1 pathway. We conducted a prospective, single‐arm study of dual‐targeted CD19/22 CAR‐T cell combined with anti‐PD‐1 antibody, tislelizumab, in R/R B‐NHL (NCT04539444). Tislelizumab was administrated on +1 day after patients received infusion of CD19/22 CAR‐T cell. Responses, survival and safety were evaluated. From 1 August 2020 to 30 March 2023, 16 patients were enrolled. The median follow‐up time is 16.0 (range: 5.0–32.0 months) months. Overall response was achieved in 14 of 16 (87.5%) patients, and the complete response (CR) was achieved in 11 of 16 (68.8%) patients. The 1‐year progression‐free survival and overall survival rates were 68.8% and 81.3%, respectively. Of the 14 patients responded, 9 patients maintained their response until the end of follow‐up. Among the 15 out of 16 (93.8%) patients who had extranodal involvement, 14 (93.3%) patients achieved overall response rate with 11 (73.3%) patients achieving CR. Eight (50%) patients experienced cytokine release syndrome. No neurologic adverse events were reported. Gene Ontology‐Biological Process enrichment analysis showed that immune response‐related signaling pathways were enriched in CR patients. Our results suggest that CD19/22 CAR‐T cell combined with tislelizumab elicit a safe and durable response in R/R B‐NHL and may improve the prognosis of those patients.
Subject
Cancer Research,Oncology,Hematology,General Medicine
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献